ABISART HCTZ

This brand name is authorized in the following countries: Australia Hong Kong

Active ingredients

The drug ABISART HCTZ contains a combination of these active pharmaceutical ingredients (APIs):

UNII J0E2756Z7N - IRBESARTAN

Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT1) antagonist. It is expected to block all actions of angiotensin-II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II (AT1) receptors results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma aldosterone concentration.

Read about Irbesartan
UNII 0J48LPH2TH - HYDROCHLOROTHIAZIDE

Hydrochlorothiazide is a diuretic and an antihypertensive agent. It affects the distal renal tubular mechanism of electrolyte reabsorption and increases excretion of sodium and chloride in approximately equivalent amounts.

Read about Hydrochlorothiazide

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
Classification
C09DA04
Irbesartan and diuretics
C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09D Angiotensin II antagonists, combinations → C09DA Angiotensin II antagonists and diuretics
Discover more medicines within C09DA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country
Identification scheme
Identifier(s)
AU
Pharmaceutical Benefits Scheme
Identifier(s): 2136K, 8404H, 8405J
HK
Department of Health Drug Office
Identifier(s): 66862, 66863, 66864

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈